Drug Type Chemical drugs |
Synonyms CID-165 |
Target |
Action inhibitors |
Mechanism CCND1 inhibitors(Cyclin D1 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Estrogen receptor positive breast cancer | Preclinical | United States | 16 Sep 2026 | |
| Hematologic Neoplasms | Preclinical | United States | 01 Jun 2025 |





